Categories
Change Password!
Reset Password!
Tapinarof cream 1%, applied once daily, works by targeting the aryl hydrocarbon receptor to reduce pro-inflammatory Th2 cytokines, strengthen the skin barrier, and combat oxidative stress.
In atopic dermatitis-affected adults and children, once-daily 1% Tapinarof cream is effective, safe, and well-tolerated.
Tapinarof cream 1%, applied once daily, works by targeting the aryl hydrocarbon receptor to reduce pro-inflammatory Th2 cytokines, strengthen the skin barrier, and combat oxidative stress. This study was performed to examine the effectiveness and safety of Tapinarof in treating moderate to severe atopic dermatitis (AD) in both adults and children (as young as 2 years old).
In two phase 3 trials spanning 8 weeks, 813 patients (pediatric and adults) were randomly assigned to receive either Tapinarof or a vehicle once daily. The key efficacy outcome was Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD) score of 0 or 1 and ≥2-grade betterment from baseline at week 8.
The primary efficacy endpoint (vIGA‐AD) was remarkably achieved in both trials: 45.4% vs. 13.9% and 46.4% vs. 18.0% (Tapinarof vs. vehicle). Eczema Area and Severity Index 75 (EASI75) responses were substantially better for Tapinarof: 55.8% vs. 22.9% and 59.1% vs. 21.2%. Rapid improvements in pruritus, as reported by patients, were also markedly more pronounced with Tapinarof. The most common adverse events (≥5%), including folliculitis, headache, and nasopharyngitis, were generally mild or moderate. Those in the Tapinarof groups exhibited lower rates of discontinuing therapy due to adverse events as opposed to the vehicle group.
Tapinarof (topical aryl hydrocarbon receptor agonist) showed outstanding efficacy, along with a favorable safety and tolerability profile, in a diverse group of AD-affected patients, including those as young as 2 years old.
Journal of the American Academy of Dermatology
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
Jonathan I Silverberg et al.
Comments (0)